Publications

Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 …

R Cohen, Q Shi, J Meyers, Z Jin, M Svrcek, C Fuchs, F Couture, P Kuebler, ...

Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance).

E Van Blarigan, C Ma, FS Ou, AP Venook, K Ng, D Niedzwiecki, ...

Discordance between central versus local response assessments in neuroendocrine tumor (NET) patients (pts) enrolled in A021202.

SM Geyer, MR Mahoney, TR Asmis, N Hall, S Karovic, MV Knopp, ...

Early-onset pancreas cancer: clinical descriptors, genomics, and outcomes

Varghese AM, Singh I, Singh R, Kunte S, Chou JF, Capanu M, Wong W, … Park W, …

Effect of celecoxib vs placebo added to standard adjuvant therapy on disease-free survival among patients with stage III colon cancer: the CALGB/SWOG 80702 (Alliance …

JA Meyerhardt, Q Shi, CS Fuchs, J Meyer, D Niedzwiecki, T Zemla, ...

Efficacy and safety of zenocutuzumab in advanced pancreatic cancer and other solid tumors harboring NRG1 fusions

AM Schram, E O’Reilly, G O’Kane

Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS

Rose Brannon A, Jayakumaran G, Diosdado M, Patel J, Razumova A, Hu Y, Meng F, Haque M, et al.

Evaluation of neratinib (N), pembrolizumab (P), everolimus (E), and nivolumab (V) in patients (pts) with fibrolamellar carcinoma (FLC).

GK Abou-Alfa, T Meyer, J Zhang, S Sherrin, A Yaqubie, A Clemens O’Neill, ...

Gemcitabine (Gem) and nab-paclitaxel (NP)±nivolumab (nivo)±CD40 agonistic monoclonal antibody APX005M (sotigalimab), in patients (Pts) with untreated metastatic pancreatic …

MH O'Hara, EM O'Reilly, RA Wolff, ZA Wainberg, AH Ko, OE Rahma, ...

IGF-binding proteins, adiponectin, and survival in metastatic colorectal cancer: results from CALGB (Alliance)/SWOG 80405

BJ Guercio, S Zhang, FS Ou, AP Venook, D Niedzwiecki, HJ Lenz, ...

Immune Landscape of Pancreas Ductal Adenocarcinoma: Current Therapeutic Strategies and Future Perspective

B Zheng-Lin, EM O’Reilly

Improving outcomes and shared decisions in pancreatic cancer using animated pancreas patient (APP) visual formats of learning: A National Pancreas Foundation (NPF) patient …

S Munigala, EM O'Reilly, M Alsante, J Holt, AH Ko, A Gelrud

Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.

K DiNardo, C Ma, FS Ou, C Yuan, BJ Guercio, V Morales-Oyarvide, ...

LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P+ Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): updated 5-year …

M Tempero, E O'Reilly, E Van Cutsem, J Berlin, P Philip, D Goldstein, ...

Leptomeningeal disease in pancreas ductal adenocarcinoma: A manifestation of longevity

O'Connor CA, Park JS, Kaley T, Kezlarian B, Edelweiss M, Yang TJ, Park W, Reidy D, et al.

Local Control and Survival After Induction Chemotherapy and Ablative Radiation Versus Resection for Pancreatic Ductal Adenocarcinoma With Vascular Involvement

Jolissaint JS, Reyngold M, Bassmann J, Seier KP, Gönen M, Varghese AM, Yu KH, Park W, et al.

MO31-6 Maintenance olaparib in Asian patients with germline BRCA-mutated metastatic pancreatic cancer

DY Oh, JO Park, HL Kindler, P Hammel, M Reni, E Van Cutsem, ...

Multimodality therapy in metastatic pancreas cancer with a BRCA mutation and durable long-term outcome: biology, intervention, or both?

TL Sutton, A Grossberg, F Ey, EM O’Reilly, BC Sheppard

MULTIOMIC BIOMARKER SIGNATURES IDENTIFY SUBSETS OF PATIENTS WHO MAY BENEFIT FROM EITHER NIVOLUMAB OR SOTIGALIMAB IN COMBINATION WITH CHEMOTHERAPY IN METASTATIC PANCREATIC CANCER

D Maurer, JX Yu, K Sklodowski, M Tognetti, L Reiter, R Bruderer, ...

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study …

PM Morice, A Leary, C Dolladille, B Chrétien, L Poulain, ...

Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations

AM Varghese, J Patel, YY Janjigian, F Meng, SD Selcuklu, G Iyer, ...

Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.

T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, MJ Hall, ...

P86. 08 phase 2 study of zenocutuzumab (MCLA-128), a bispecific HER2/HER3 antibody in NRG1 fusion-positive advanced solid tumors

A Schram, T Macarulla, E O’Reilly, J Rodon, B Wolpin, S Ou, D Kim, ...

Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes

Momtaz P, O'Connor CA, Chou JF, Capanu M, Park W, Bandlamudi C, Berger MF, Kelsen DP, et al.

Pancreas cancer: Therapeutic trials in metastatic disease

Smithy JW, O'Reilly EM

Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma

Askan G, Sahin IH, Chou JF, Yavas A, Capanu M, Iacobuzio-Donahue CA, Basturk O, O'Reilly EM

Pancreatic cancer: a review

Park W, Chawla A, O'Reilly EM

Pancreatic cancer: a review (vol 326, pg 851, 2021)

W Park, A Chawla, EM O'Reilly

Persistent disparities in treatment and survival for patients with pancreatic cancer despite insurance expansion policies

LV Saadat, JF Chou, M Gonen, KC Soares, VP Balachandran, ...

Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer

Joshi S, Gomes ED, Wang T, Corben A, Taldone T, Gandu S, Xu C, Sharma S, et al.

POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).

LH Schwartz, HL Kindler, P Hammel, M Reni, E Van Cutsem, T Macarulla, ...

POLO: subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

D Arnold, T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, ...

Preoperative CT predictors of survival in patients with pancreatic ductal adenocarcinoma undergoing curative intent surgery

SM Dickinson, CA McIntyre, JB Schilsky, KA Harrington, SR Gerst, ...

Prognostic value of the Memorial Sloan Kettering Prognostic Score in metastatic pancreatic adenocarcinoma

Lebenthal JM, Zheng J, Glare PA, O'Reilly EM, Yang AC, Epstein AS

Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.

R Cohen, Q Shi, JP Meyers, Z Jin, M Svrcek, CS Fuchs, F Couture, ...

Radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib+/-doxorubicin: Correlative science from CALGB 80802 …

L Dercle, SM Geyer, AB Nixon, F Innocenti, Q Shi, SB Jacobson, L Luk, ...

Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial

Goodman KA, Ou FS, Hall NC, Bekaii-Saab T, Fruth B, Twohy E, Meyers MO, Boffa DJ, et al.

Randomized phase II trial of olaparib+ pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (g BRCA …

V Chung, KA Guthrie, MJ Pishvaian, AM Lowy, EG Chiorean, MT Duong, ...

Real-world overall survival of patients diagnosed with recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC).

EM O'Reilly, KH Yu, N Lamarre, A Surinach, P Cockrum

Retrospective Case Series Analysis of RAF Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies

A Hendifar, EM Blais, B Wolpin, V Subbiah, E Collisson, I Singh, ...

Targeting DNA Damage Repair Mechanisms in Pancreas Cancer

Perkhofer L, Golan T, Cuyle PJ, Matysiak-Budnik T, Van Laethem JL, Macarulla T, Cauchin E, Kleger A, et al.

Targeting DNA damage repair pathways in pancreas cancer

Crowley F, Park W, O'Reilly EM

Therapeutic Implications of Germline Testing in Patients With Advanced Cancers

Stadler ZK, Maio A, Chakravarty D, Kemel Y, Sheehan M, Salo-Mullen E, Tkachuk K, Fong CJ, et al.

Treatment patterns and survival in patients with early-onset pancreatic cancer

Saadat LV, Chou JF, Gonen M, Soares KC, Kingham TP, Varghese AM, Jarnagin WR, D'Angelica MI, et al.

1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer: Phase III …

D Hochhauser, H Kindler, P Hammel, M Reni, E Van Cutsem, T Macarulla, ...

A mixed methods analysis of patients’ advance care planning values in outpatient oncology: Person-Centered Oncologic Care and Choices (P-COCC)

R Agarwal, E Shuk, D Romano, M Genoff, Y Li, EM O’Reilly, W Breitbart, ...

A multicenter randomized three‐arm phase II study of (1) everolimus,(2) estrogen deprivation therapy (EDT) with leuprolide+ letrozole, and (3) everolimus+ EDT in patients with …

I El Dika, RJ Mayer, AP Venook, M Capanu, MP LaQuaglia, R Kobos, ...

A phase I study to evaluate the safety and tolerability of AB680 combination therapy in participants with gastrointestinal malignancies.

JC Bendell, GA Manji, S Pant, DW Lai, J Colabella, W Berry, MC Paoloni, ...

A phase I/II study of GB1275, a first-in-class oral CD11b modulator, alone, and combined with pembrolizumab in specified advanced solid tumors or with chemotherapy in …

DW Rasco, JC Bendell, A Wang-Gillam, W Park, EM O'Reilly, L Zhou, ...

A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors

AM Schram, AE Drilon, T Macarulla, EM O'Reilly, J Rodon, BM Wolpin, ...